Pathogenesis of dermatomyositis: Role of cytokines and interferon

Current Rheumatology Reports

Volumn 13, Issue 3, 2011, Pages 225-232

  Kao, Lily ^a   Chung, Lorinda ^a   Fiorentino, David F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; Dermatomyositis; Interface dermatitis; Interferon

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERFERON 3; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; DERMATOMYOSITIS; DISEASE ACTIVITY; HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MUSCLE DISEASE; PATHOGENESIS; PHENOTYPE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN DISEASE; UPREGULATION;

CYTOKINES; DERMATOMYOSITIS; HUMANS; INTERFERONS; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION; SKIN;

EID: 79957455821     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0166-x     Document Type: Article

References (50)

1. MC Dalakas R Hohlfeld 2003 Polymyositis and dermatomyositis Lancet 362 9388 971 82 14511932 10.1016/S0140-6736(03)14368-1 1:CAS:528: DC%2BD3sXnsVWqu7g%3D (Pubitemid 37159295)
2. M Caproni, et al. 2004 Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis Br J Dermatol 151 4 784 91 15491417 10.1111/j.1365-2133.2004.06144.x 1:CAS:528:DC%2BD2cXhtVKitr3F (Pubitemid 39482111)
3. SA Greenberg D Fiorentino 2009 Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle Br J Dermatol 160 2 464 5 19077075 10.1111/j.1365-2133.2008.08967.x 1:STN:280: DC%2BD1M7htlajsg%3D%3D
4. S Salomonsson IE Lundberg 2006 Cytokines in idiopathic inflammatory myopathies Autoimmunity 39 3 177 90 16769651 10.1080/08916930600622256 1:CAS:528:DC%2BD28XnsFGltb4%3D (Pubitemid 43879030)
5. B De Paepe KK Creus JL De Bleecker 2009 Role of cytokines and chemokines in idiopathic inflammatory myopathies Curr Opin Rheumatol 21 6 610 6 19726994 10.1097/BOR.0b013e3283317b31
6. G Mamyrova, et al. 2008 Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis Arthritis Rheum 58 12 3941 50 19035492 10.1002/art.24039 1:CAS:528:DC%2BD1MXmt1ylug%3D%3D This was a large study of JDM patients showing that multiple TNF-α and IL-1 polymorphisms are risk and protective factors for JDM and that the TNF-α-308A allele has a much higher relative importance compared with all detected risk and other TNF-α and IL-1 cytokine polymorphisms
7. TB Niewold, et al. 2010 Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis J Pediatr 157 4 653 7 20605164 10.1016/j.jpeds.2010.04.034 1:CAS:528:DC%2BC3cXhtFWqtb7F
8. M Dastmalchi, et al. 2008 A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies Ann Rheum Dis 67 12 1670 7 18272672 10.1136/ard.2007.077974 1:CAS:528: DC%2BD1MXjs1OitA%3D%3D This study combined clinical, serologic, and histopathologic data from muscle to document that flares in DM (and other inflammatory myopathies) are seen following infliximab therapy, and provides some molecular evidence that these flares are associated with increased IFN activity in the blood and muscle
9. Y Ishikawa, et al. 2010 Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature Clin Rheumatol 29 5 563 6 20143116 10.1007/s10067-009-1370-1
10. M Marino, et al. 2008 IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human myoblasts J Neuroimmunol 196 1-2 41 8 18400310 10.1016/j.jneuroim.2008. 02.005 1:CAS:528:DC%2BD1cXmsFKms7w%3D
11. A Tournadre V Lenief P Miossec 2010 Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines Arthritis Rheum 62 7 2144 51 20309865 1:CAS:528:DC%2BC3cXht1aqsL3I This was the first demonstration of TLR3 and TLR7 expression by inflammatory cells and myoblasts in DM, demonstrating preferential expression in regenerating myoblasts that is stimulated by dying myoblasts or nucleic acids, which might provide a mechanism for feed-forward acceleration of IFN production and inflammation
12. H Bilgic, et al. 2009 Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis Arthritis Rheum 60 11 3436 46 19877033 10.1002/art.24936 1:CAS:528:DC%2BD1MXhsFentLzK Investigators showed a positive correlation between blood levels of three IFN-induced chemokines, IL-6, and disease activity in DM. It is the largest study to date to correlate validated clinical activity measures with levels of circulating candidate biomarker proteins in adult patients with DM
13. T Sugiura, et al. 2002 Increased IL-15 production of muscle cells in polymyositis and dermatomyositis Int Immunol 14 8 917 24 12147628 10.1093/intimm/dxf062 1:CAS:528:DC%2BD38XmsVKjtbk%3D
14. J Suzuki, et al. 2001 Serum levels of interleukin 15 in patients with rheumatic diseases J Rheumatol 28 11 2389 91 11708407 1:CAS:528: DC%2BD3MXpt1Whsbs%3D (Pubitemid 33031965)
15. Mielnik P, et al. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2010.
16. G Page G Chevrel P Miossec 2004 Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells Arthritis Rheum 50 1 199 208 14730617 10.1002/art.11428 1:CAS:528:DC%2BD2cXht1Kru7k%3D (Pubitemid 38084305)
17. P Szodoray, et al. 2010 Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand Rheumatology (Oxford) 49 10 1867 77 10.1093/rheumatology/keq151 1:CAS:528:DC%2BC3cXhtFGhtLfE
18. M Tucci, et al. 2007 Increased IL-18 production by dendritic cells in active inflammatory myopathies Ann NY Acad Sci 1107 184 92 17804546 10.1196/annals.1381.020 1:CAS:528:DC%2BD2sXhtVShs7jK (Pubitemid 47528795)
19. T Gono, et al. 2010 Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease Rheumatology (Oxford) 49 10 1878 81 10.1093/rheumatology/keq196 1:CAS:528:DC%2BC3cXhtFGhtb7O
20. O Krystufkova, et al. 2009 Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies Ann Rheum Dis 68 6 836 43 18628284 10.1136/ard.2008.091405 1:CAS:528: DC%2BD1MXotVCjtLY%3D
21. E Antiga, et al. 2010 Characterization of regulatory T cells in patients with dermatomyositis J Autoimmun 35 4 342 50 20843660 10.1016/j.jaut.2010.07.006 1:CAS:528:DC%2BC3cXhtlCgtrjN
22. E Hagiwara, et al. 1996 Abnormal numbers of cytokine producing cells in patients with polymyositis and dermatomyositis Clin Exp Rheumatol 14 5 485 91 8913649 1:STN:280:DyaK2s%2FntVOhsQ%3D%3D (Pubitemid 26335471)
23. AB Hassan, et al. 2006 Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis J Autoimmun 27 1 62 8 16895750 10.1016/j.jaut.2006.06.003 1:CAS:528:DC%2BD28Xosl2qsL8%3D (Pubitemid 44294854)
24. JC Hall A Rosen 2010 Type I interferons: crucial participants in disease amplification in autoimmunity Nat Rev Rheumatol 6 1 40 9 20046205 10.1038/nrrheum.2009.237 1:CAS:528:DC%2BC3cXotlSh This is an outstanding review of IFN and its relationship to autoimmunity
25. SA Greenberg 2010 Type 1 interferons and myositis Arthritis Res Ther 12 Suppl 1 S4 20392291
26. SA Greenberg, et al. 2005 Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis Ann Neurol 57 5 664 78 15852401 10.1002/ana.20464 1:CAS:528:DC%2BD2MXkvFykt78%3D (Pubitemid 40628855)
27. Magro CM, et al. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol. 2010;37(6):659-71.
28. ML Eloranta, et al. 2007 A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies Arthritis Rheum 56 9 3112 24 17763410 10.1002/art.22860 1:CAS:528:DC%2BD2sXht1GgtbrO (Pubitemid 47502759)
29. B Kea R Pesich L Chung P Brown D Fiorentino 2007 Fiorentino D, Genomic analyses identify abnormalities in lipid metabolism in dermatomyositis patients J Invest Dermatol 127 S1 12
30. J Wenzel T Tuting 2008 An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis." J Invest Dermatol 128 10 2392 402 18418411 10.1038/jid.2008.96 1:CAS:528:DC%2BD1cXhtFSltbzO This is an excellent review of the relationship between IFN signature and interface dermatitis in the skin
31. RJ Walsh, et al. 2007 Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis Arthritis Rheum 56 11 3784 92 17968926 10.1002/art.22928 1:CAS:528:DC%2BD2sXhsVSkt7bL (Pubitemid 350100711)
32. EC Baechler, et al. 2007 An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity Mol Med 13 1-2 59 68 17515957 1:CAS:528:DC%2BD2sXmt12rsLg%3D (Pubitemid 46786834)
33. M Salajegheh, et al. 2010 Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy Ann Neurol 67 1 53 63 20186858 10.1002/ana.21805 1:CAS:528:DC%2BC3cXksVGgu7s%3D This was the first report to indicate that the ubiquitin conjugating system is activated in the muscle of DM patients and that abnormal protein conjugates with ISG-15 protein are present in tissue and inducible by type 1 IFN. It correlates expression of these proteins involved in conjugation with perifascicular atrophy of muscle fibers
34. N Fall, et al. 2005 Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy Arthritis Rheum 52 10 3175 80 16200621 10.1002/art.21303 1:CAS:528:DC%2BD2MXhtF2msrvO (Pubitemid 41447100)
35. J Wenzel, et al. 2006 Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis Clin Exp Dermatol 31 4 576 82 16716166 10.1111/j.1365-2230.2006.02150.x 1:STN:280:DC%2BD283oslSluw%3D%3D (Pubitemid 43806596)
36. KA O'Connor, et al. 2006 MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement Clin Immunol 120 3 319 25 16859997 10.1016/j.clim.2006.05.011 (Pubitemid 44175902)
37. T Lovgren, et al. 2004 Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG Arthritis Rheum 50 6 1861 72 15188363 10.1002/art.20254 (Pubitemid 38725099)
38. Krol P, et al. Serum levels of interferon {alpha} do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis. 2010. This study failed to find a positive correlation with circulating IFN-α levels and muscle disease activity in patients with DM as measured by MRI of muscles. It suggests that the relationship between IFN-α levels, the IFN signature in blood, and disease activity in DM is complex.
39. KB Stone, et al. 2007 Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy Arthritis Rheum 56 9 3125 31 17763431 10.1002/art.22865 1:CAS:528:DC%2BD2sXht1GgtbrP (Pubitemid 47502760)
40. J Hua, et al. 2006 Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies Arthritis Rheum 54 6 1906 16 16736505 10.1002/art.21890 1:CAS:528:DC%2BD28Xms1Sisr8%3D (Pubitemid 43877940)
41. TB Niewold, et al. 2009 Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy Arthritis Rheum 60 6 1815 24 19479879 10.1002/art.24555 1:CAS:528:DC%2BD1MXotVeqt70%3D
42. T Sugiura, et al. 2000 Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production J Immunol 164 12 6593 600 10843719 1:CAS:528:DC%2BD3cXktFWlurs%3D (Pubitemid 30408846)
43. I Lundberg, et al. 1997 Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies Arthritis Rheum 40 5 865 74 9153548 10.1002/art.1780400514 1:CAS:528:DyaK2sXjsV2hsLw%3D (Pubitemid 27200003)
44. MedImmune LLC A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis. In: ClinicalTrials.gov [Internet] 2000- [cited 2010 Dec 16]; Available from: http://clinicaltrials.gov/ct2/show/ NCT00533091 NLM Identifier: NCT00533091.
45. M Swiecki M Colonna 2010 Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance Immunol Rev 234 1 142 62 20193017 10.1111/j.0105-2896.2009.00881.x 1:CAS:528: DC%2BC3cXjslart74%3D
46. JM McNiff DH Kaplan 2008 Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus J Cutan Pathol 35 5 452 6 18005168 10.1111/j.1600-0560.2007.00848.x This is a comparison of the histologic location of pDCs in the skin of DM patients versus lupus patients. This paper provides evidence suggesting that pDCs might have different functions in different autoimmune skin diseases due to their different locations (Pubitemid 351519413)
47. Lopez de Padilla CM, et al. 2007 Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis Arthritis Rheum 56 5 1658 68 10.1002/art.22558 (Pubitemid 46764095)
48. S Shrestha, et al. 2010 Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells Arthritis Rheum 62 9 2813 22 20506305 10.1002/art.27529
49. Zahn S, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131(1):133-40.
50. JN Fleming, et al. 2008 Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3 1 e1452 18197262 10.1371/journal.pone. 0001452 (Pubitemid 351248269)